{"keywords": [{"value": "Pershing Square Capital Management", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Valeant Pharmaceuticals International Inc", "rank": "2", "is_major": "Y", "name": "organizations"}, {"value": "Ackman, William A", "rank": "3", "is_major": "Y", "name": "persons"}, {"value": "Drugs (Pharmaceuticals)", "rank": "4", "is_major": "Y", "name": "subject"}, {"value": "Philidor Rx Services LLC", "rank": "5", "is_major": "N", "name": "organizations"}], "headline": {"print_headline": "Ackman Speaks Up for Valeant", "main": "Speaking Up for Valeant, Ackman Emphasizes the Long Term"}, "byline": {"original": "By MATTHEW GOLDSTEIN", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "GOLDSTEIN", "firstname": "Matthew"}]}, "web_url": "http://www.nytimes.com/2015/10/31/business/dealbook/speaking-up-for-valeant-william-ackman-emphasizes-the-long-term.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "5633bc5e38f0d85e68a21d8a", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/31/business/31db-Ackman/31db-Ackman-thumbWide.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/31/business/31db-Ackman/31db-Ackman-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargeheight": "400", "xlargewidth": "600", "xlarge": "images/2015/10/31/business/31db-Ackman/31db-Ackman-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/31/business/31db-Ackman/31db-Ackman-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/31/business/31db-Ackman/31db-Ackman-thumbStandard.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/31/business/31db-Ackman/31db-Ackman-thumbStandard.jpg"}], "pub_date": "2015-10-31T00:00:00Z", "print_page": "7", "section_name": "Business Day", "word_count": "901", "blog": [], "news_desk": "Business", "snippet": "As defenses go, it was an odd one. The hedge fund investor said he expected the drug maker to be investigated by regulators and prosecutors for years.", "document_type": "article", "abstract": "Pershing Square Capital Management's William A Ackman defends hedge fund's large investment in Valeant Pharmaceuticals International, embattled drug company whose stock price has fallen more than 40 percent in past two weeks.", "lead_paragraph": "As defenses go, it was an odd one. The hedge fund investor said he expected the drug maker to be investigated by regulators and prosecutors for years."}